Clinical trials: Insomnia Disorder
Circadian Dysregulation
Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers
The purpose of this study to determine the degree to which ramelteon, once daily (QD), can reduce the insomnia symptoms associated with rapid, eastward travel across 5 time zones.
- Trial name
- NCT00492011
- Testing
- Ramelteon
- Where
- 4 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Takeda
Sleep Quality
Comparison of Four Qualia Sleep Formulations on Sleep Quality : An Open-label 4-arm Pilot Study
This is a randomized, open-label, 4-arm pilot study designed to evaluate the efficacy and tolerability of four Qualia Sleep formulations (Formulas A, B, C, and D) in healthy adults aged 18 years and older who report poor sleep…
- Trial name
- NCT07744971
- Testing
- Qualia Sleep Formula A, Qualia Sleep Formula B, Qualia Sleep Formula C
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Qualia Life Sciences
Insomnia
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1.
- Trial name
- NCT01209728
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Depressive Disorder, Major
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.
- Trial name
- NCT00368030
- Testing
- Eszopiclone
- Where
- 65 sites in United States
- Volunteers
- 545 people
- Sponsor
- Sumitomo Pharma America, Inc.
Sleep Quality, Menopausal Symptoms
Sleep Quality in CHIMES (MF101)
Menopausal women often complain of difficulty sleeping and the transition from pre- to postmenopausal status is associated with an incresase in self-reported sleep disturbance.
- Trial name
- NCT00454441
- Testing
- MF101
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Bionovo
Insomnia Disorder
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the…
- Trial name
- NCT06279286
- Testing
- HS-10506
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Insomnia
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.
This purpose of this study is to assess the efficacy and safety of Ramelteon, once daily (QD), in elderly subjects with chronic insomnia.
- Trial name
- NCT00671294
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Takeda
Menopause Related Conditions
ProGo Menopause Wellbeing Study
This study will evaluate whether ProGo®, a salmon protein hydrolysate (SPH), helps to moderate body mass index (BMI) and improve quality of life (QoL) in menopausal women.
- Trial name
- NCT07611305
- Testing
- Salmon protein hydrolysate (SPH) powder formulated into a tablet format, Microcrystalline Cellulose
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hofseth Biocare ASA
Insomnia, Major Depressive Disorder
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.
- Trial name
- NCT02669082
- Testing
- Ramelteon
- Where
- 7 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Takeda
Sleep, Pollution; Exposure
Investigating the Effect of Daily CARDIO® Capsules Supplementation on Improved Sleep in Healthy, Urban-Dwelling Adults
This study aims to explore the impact of supplementation with CARDIO® whole salmon oil capsules on healthy adult participants with sleep disruption related to particulate matter pollution.
- Conditions
- Sleep, Pollution; Exposure, Cough
- Trial name
- NCT06768970
- Testing
- CARDIO® salmon oil
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Hofseth Biocare ASA
Transient Insomnia
SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.
The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty…
- Trial name
- NCT03331042
- Testing
- SM-1, D+Z, D+L
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Sequential Medicine Ltd
Insomnia Disorder
Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder.
- Trial name
- NCT02350309
- Testing
- Lemborexant 5 mg, Lemborexant 10 mg, Flurazepam 30 mg
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eisai Inc.
Primary Insomnia
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
A polysomnography study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in adult subjects with primary insomnia.
- Trial name
- RESTORA 1 (NCT00608985)
- Testing
- almorexant, zolpidem
- Where
- 91 sites in Australia, Austria and 18 more
- Volunteers
- 709 people
- Sponsor
- Midnight Pharma, LLC
Insomnia Chronic
Effect of Medical Hypnosis in Virtual Reality on Insomnia Disorders
The prevalence of chronic insomnia is 13.3% in France in 2019 (8.9 million). The consequences for these people are multiple: drowsiness, memory problems, difficulty concentrating, anxiety.
- Trial name
- EMERITE (NCT04712825)
- Testing
- Cognitive-behavioural therapy, HypnoVR® device
- Where
- France
- Volunteers
- 20 people
- Sponsor
- HypnoVR
Insomnia
Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia
Insomnia is a common sleep disorder in which a person has difficulty falling asleep or staying asleep or getting good quality sleep.
- Trial name
- NCT05840822
- Testing
- Cannabidiol (CBD) Capsule 75mg
- Where
- 5 sites in Australia
- Volunteers
- 519 people
- Sponsor
- Avecho Biotechnology
Insomnia
Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
Assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep
- Trial name
- NCT06021795
- Testing
- Sound Treatment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Third Wave Therapeutics
Primary Insomnia
Comparison of Two Temperatures to Treat Insomnia
Insomnia patients demonstrate subjective and physiological hyperarousal. The Cereve Sleep System has been proposed as a clinical treatment to reverse this hyperarousal in insomnia patients.
- Trial name
- NCT01790256
- Testing
- Cereve Sleep System at 30 degrees C, Cereve Sleep System at 14-16 degrees C
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Cereve, Inc.
Insomnia
Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-02)
The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.
- Trial name
- NCT05809544
- Testing
- WELT-IP
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- WELT corp
Patients with Insomnia
Late Phase II Study of TS-142 in Patients with Insomnia
This is a randomized, double-blind, multi-center, placebo-controlled, parallel-group exploratory study in patients with insomnia.
- Trial name
- NCT04469023
- Testing
- TS-142
- Where
- Japan
- Volunteers
- 179 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Insomnia
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
This study will establish the safety and tolerability of suvorexant (MK-4305) when administered for up to 14 months. Participants will be randomized to receive suvorexant or placebo for a 12-month double-blind (DB) Treatment…
- Trial name
- NCT01021813
- Testing
- Suvorexant
- Volunteers
- 781 people
- Sponsor
- Merck Sharp & Dohme LLC